Price Chart

Executive Summary

Medline Inc. completed a major balance-sheet restructuring on May 28, 2026, issuing $2.0B in new senior secured notes ($1.25B 5.000% notes due 2031 and $750M 5.250% notes due 2033) and refinancing its term loan facility with a new $2.75B 2033 term loan, while concurrently an equity offering of ~72.6M shares at $37/sh by selling stockholders closed. Net proceeds from the notes and term loan, plus cash on hand, were used to repay the existing 2028 term loan, refinance ~$724M of the 2030 term loan, redeem ~$500M of the 6.250% secured notes due 2029, and pay fees. The equity offering—a secondary sale by Blackstone, H&F, and ADIA affiliates—does not raise capital for the company but further monetizes sponsor stakes.

Key Financial Metrics

Key Facts

• Issued $1.25B 5.000% senior secured notes due 2031 and $750M 5.250% senior secured notes due 2033 under a new indenture dated May 28, 2026.
• Entered into Amendment No. 7 to the credit agreement, providing a new $2.75B senior secured term loan facility due May 28, 2033 (2033 Refinancing Term Loan Facility).
• Proceeds from the notes offering and new term loan, plus cash on hand, were used to repay the existing 2028 term loan in full, refinance ~$724M of the 2030 term loan, redeem ~$500M of the 6.250% Senior Secured Notes due 2029, and pay related fees.
• Certain selling stockholders affiliated with Blackstone, Hellman & Friedman, and ADIA completed an underwritten public offering of 72,554,594 shares of Class A common stock at $37.00 per share.
• The underwriters were granted a 30-day option to purchase up to an additional 10,883,189 shares.
• Affiliates of Blackstone and Carlyle each beneficially own more than 10% of the company's outstanding common stock; the equity offering involved conflicted underwriters (Blackstone Securities Partners and TCG Capital Markets) under FINRA Rule 5121.
• The notes and guarantees are senior secured, ranking pari passu with the existing secured credit facilities and existing secured notes, and are collateralized by substantially all assets of the issuers and guarantors.

Financial Impact

Approximately $2.0B in new senior secured notes and $2.75B in new term loans issued; ~$500M of 6.250% notes redeemed; outstanding 2028 term loan fully repaid.

Risk Factors

• Secondary stock overhang from the 30-day underwriter option to purchase up to ~10.9M additional shares could pressure MDLN in the near term.
• The substantial debt load (new $2.0B notes + $2.75B term loan, plus existing secured notes and revolver) keeps leverage elevated, and a downturn in surgical/medical demand could strain coverage ratios.
• The refinancing does not address any operational performance issues; fundamentals may lag if revenue softens.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status